Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 9/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504152 | 0.89 | CCR8 (0.52) | SPHK1MGLLCCR8KMT2AMEN1 | |
| SCHEMBL6501382 | 0.87 | KMT2A (0.54) | FAAHSPHK1CCR8KMT2AMEN1 | |
| SCHEMBL6505185 | 0.82 | CCR8 (0.45) | SPHK1MGLLCCR8KMT2AMEN1 | |
| SCHEMBL2855574 | 0.81 | KDM4E (0.46) | SPHK1KMT2AMAOBMAOA | |
| SCHEMBL2699801 | 0.80 | SPHK1 (0.49) | SPHK1MAOBMAOAKCNH2 | |
| SCHEMBL3873697 | 0.76 | SSTR5 (0.45) | SPHK1MAOBMAOAKCNH2 | |
| SCHEMBL7067317 | 0.76 | FAAH (0.55) | FAAHMGLLCCR8KCNH2 | |
| SCHEMBL14142405 | 0.74 | GAA (0.46) | SPHK1MAOBMAOA | |
| SCHEMBL2852932 | 0.73 | MAOB (0.47) | SPHK1MAOBMAOA | |
| SCHEMBL6505677 | 0.72 | CCR8 (0.54) | MGLLCCR8KMT2AMEN1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | FAAH 664/4885SPHK1 541/4885MGLL 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.